Björn Schneider

16PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersMolecular targetsNeonatologyCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 30, 2026
Hsa-miR-25-3p Inhibition Sensitizes Patient-Derived Glioblastoma Cells to Temozolomide via β-catenin Downregulation.

|Aug 02, 2025
CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid-a promising combination strategy for therapeutic intervention.

Fatemeh Shokraie, Larissa Lechermeier, Pia Bordihn

|Dec 31, 2024
On TRacK With Larotrectinib in a Neonate With a Giant Congenital ETV6::NTRK3 Fusion-Positive Infantile Fibrosarcoma of the Head and Neck.

Teresa M Cardesa-Salzmann, Monika Sparber-Sauer, Peter Hingst

|Oct 26, 2024
Correction: Becker et al. Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response. Cancers 2023, 15, 5597.

Anne-Sophie Becker, Cornelius Kluge, Carsten Schofeld

|Jul 25, 2024
Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma.

Thomas Freitag, Philipp Kaps, Justus Ramtke

|Dec 09, 2023
Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response.

Anne-Sophie Becker, Cornelius Kluge, Carsten Schofeld

Pageof 3

Frequent Collaborators

8 joint publications

Claudia Maletzki

3 joint publications

Heiko Lemcke

2 joint publications

Anna Skorska

2 joint publications

Caterina Redwanz